×
About 19,180 results

ALLMedicine™ Ankylosing Spondylitis Center

Research & Reviews  7,801 results

When Can One-level Pedicle Subtraction Osteotomy Obtain Satisfied Outcomes for Severe T...
https://doi.org/10.1097/BRS.0000000000003800
Spine Huang JC, Qian BP et. al.

Feb 23rd, 2021 - A retrospective study. The aim of this study was to make a thorough comparison of clinical and radiographic outcomes between ankylosing spondylitis (AS) patients with severe kyphosis who underwent one- or two-level pedicle subtraction osteotomy (P...

Macrophage migration inhibitory factor may play a protective role in osteoarthritis.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7896408
Arthritis Research & Therapy; Liu M, Xie Z et. al.

Feb 21st, 2021 - Osteoarthritis (OA) is the most prevalent form of arthritis and the major cause of disability and overall diminution of quality of life in the elderly population. Currently there is no cure for OA, partly due to the large gaps in our understanding...

Epigenetics of ankylosing spondylitis: Recent developments.
https://doi.org/10.1111/1756-185X.14080
International Journal of Rheumatic Diseases; Yang H, Chen Y et. al.

Feb 20th, 2021 - Ankylosing spondylitis (AS) is a chronic inflammatory autoimmune disease which mainly affects the spine, sacroiliac joint and peripheral joints. To date, the exact causes and pathogenesis of AS still remain unknown. It is considered that the patho...

Primary Total Hip Arthroplasty in Patients With Ankylosing Spondylitis.
https://doi.org/10.1016/j.arth.2021.01.054
The Journal of Arthroplasty; Bukowski BR, Clark NJ et. al.

Feb 19th, 2021 - Ankylosing spondylitis (AS) is a common inflammatory spondyloarthropathy with hip involvement in 40% of patients. With the renewed interest in the hip-spine interplay, this study aimed to define long-term outcomes of primary total hip arthroplasty...

see more →

Guidelines  37 results

2019 Update of the American College of Rheumatology/ Spondylitis Association of America/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis ...
https://www.rheumatology.org/Portals/0/Files/AxialSpA-Guideline-2019.pdf
Ward MM,et al

Sep 30th, 2019 - To update evidence-based recommendations for the treatment of patients with ankylosing spondylitis (AS) and nonradiographic axial spondyloarthritis (SpA). ankylosing spondylitis

2019 Update of the American College of Rheumatology/Spondylitis Association of America/...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6764882
Arthritis & Rheumatology (Hoboken, N.J.); Ward MM, Deodhar A et. al.

Aug 22nd, 2019 - To update evidence-based recommendations for the treatment of patients with ankylosing spondylitis (AS) and nonradiographic axial spondyloarthritis (SpA). We conducted updated systematic literature reviews for 20 clinical questions on pharmacologi...

FDA Approves Samsung Bioepis' HADLIMA™ (adalimumab-bwwd)
https://www.businesswire.com/news/home/20190723006033/en/FDA-Approves-Samsung-Bioepis-HADLIMA%E2%84%A2-adalimumab-bwwd

Jul 23rd, 2019 - Samsung Bioepis Co., Ltd. today announced that the US Food and Drug Administration (FDA) has approved HADLIMA™ (adalimumab-bwwd), a biosimilar referencing HUMIRA® i (adalimumab), for the treatment of rheumatoid arthritis, juvenile idiopathic arthr...

FDA Approves ETICOVO™ (etanercept-ykro), Samsung Bioepis' Second Anti-TNF Medicine in the United States
http://www.samsungbioepis.com/en/newsroom/detail/FDA-Approves-ETICOVO-Samsung-Bioepis-Second-Anti-TNF-Medicine.html

Apr 28th, 2019 - Samsung Bioepis Co., Ltd. today announced that the US Food and Drug Administration (FDA) has approved ETICOVO™ (etanercept-ykro), a biosimilar referencing ENBREL® (etanercept), across all eligible indications for the treatment of rheumatoid arthri...

2017 American College of Rheumatology/American Association of Hip and Knee Surgeons Guidelin...
https://www.rheumatology.org/Portals/0/Files/ACR-AAHKS-Perioperative-Management-Guideline.pdf
Goodman, S.,et al

Jul 31st, 2017 - This collaboration between the American College of Rheumatology and the American Association of Hip and Knee Surgeons developed an evidence-based guideline for the perioperative management of antirheumatic drug therapy for adults with rheumatoid a.

see more →

Drugs  1,113 results see all →

Clinicaltrials.gov  9,409 results

When Can One-level Pedicle Subtraction Osteotomy Obtain Satisfied Outcomes for Severe T...
https://doi.org/10.1097/BRS.0000000000003800
Spine Huang JC, Qian BP et. al.

Feb 23rd, 2021 - A retrospective study. The aim of this study was to make a thorough comparison of clinical and radiographic outcomes between ankylosing spondylitis (AS) patients with severe kyphosis who underwent one- or two-level pedicle subtraction osteotomy (P...

Diclofenac sodium delayed release - diclofenac sodium tablet, delayed release-NuCare Pharmaceuticals,Inc.
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5b4c1a15-ed93-7192-e053-2991aa0a8360

Feb 22nd, 2021 - Carefully consider the potential benefits and risks of diclofenac sodium delayed-release tablets and other treatment options before deciding to use diclofenac. Use the lowest effective dose for the shortest duration consistent with individual pati...

Naproxen - naproxen tablet-REMEDYREPACK INC.
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=88a548d1-97c0-46d0-825a-75ef689d6470

Feb 21st, 2021 - Naproxen tablets and naproxen sodium tablets are indicated for: the relief of the signs and symptoms of: rheumatoid arthritis osteoarthritis ankylosing spondylitis Polyarticular Juvenile Idiopathic Arthritis Naproxen tablets and naproxen sodium ta...

Celecoxib - celecoxib capsule-NuCare Pharmaceuticals,Inc.
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7beaec08-56f0-0081-e053-2991aa0ac0d4

Feb 21st, 2021 - Celecoxib is indicated Celecoxib is a nonsteroidal anti-inflammatory drug indicated for: Osteoarthritis (OA) ( 1.1) Rheumatoid Arthritis (RA) ( 1.2) Juvenile Rheumatoid Arthritis (JRA) in patients 2 years and older ( 1.3) Ankylosing Spondylitis (A...

see more →

News  769 results

Tofacitinib Effective for Ankylosing Spondylitis in Phase 3
https://www.staging.medscape.com/viewarticle/940709

Nov 9th, 2020 - Patients with active ankylosing spondylitis (AS) experienced rapid clinical response to the oral Janus kinase (JAK) inhibitor tofacitinib (Xeljanz) in a phase 3, randomized, double-blind, placebo-controlled study. Tofacitinib was significantly mor...

Tofacitinib Effective for Ankylosing Spondylitis in Phase 3
https://www.medscape.com/viewarticle/940709

Nov 9th, 2020 - Patients with active ankylosing spondylitis (AS) experienced rapid clinical response to the oral Janus kinase (JAK) inhibitor tofacitinib (Xeljanz) in a phase 3, randomized, double-blind, placebo-controlled study. Tofacitinib was significantly mor...

Fast Five Quiz: Ankylosing Spondylitis Signs and Symptoms
https://reference.medscape.com/viewarticle/932588_4

Jul 1st, 2020 - The age of onset of AS is usually from the late teens to 40 years. Onset in persons older than 50 years is unusual, although diagnosis of mild or asymptomatic disease may be made at a later age. Insidious onset of low back pain is the most common ...

Fast Five Quiz: Ankylosing Spondylitis Signs and Symptoms
https://reference.medscape.com/viewarticle/932588_1

Jul 1st, 2020 - Ankylosing spondylitis (AS) is a chronic, multisystem inflammatory disorder primarily affecting the axial skeleton and sacroiliac joints. AS is one of the seronegative spondyloarthropathies, which are multisystem inflammatory diseases that affect ...

Fast Five Quiz: Ankylosing Spondylitis Signs and Symptoms
https://reference.medscape.com/viewarticle/932588

Jul 1st, 2020 - Ankylosing spondylitis (AS) is a chronic, multisystem inflammatory disorder primarily affecting the axial skeleton and sacroiliac joints. AS is one of the seronegative spondyloarthropathies, which are multisystem inflammatory diseases that affect ...

see more →

Patient Education  51 results see all →